HBIO
Price
$2.17
Change
-$0.11 (-4.82%)
Updated
Nov 13 closing price
112 days until earnings call
IRMD
Price
$55.45
Change
-$1.50 (-2.63%)
Updated
Nov 13 closing price
84 days until earnings call
Ad is loading...

HBIO vs IRMD

Header iconHBIO vs IRMD Comparison
Open Charts HBIO vs IRMDBanner chart's image
Harvard Bioscience
Price$2.17
Change-$0.11 (-4.82%)
Volume$211.37K
CapitalizationN/A
iRadimed
Price$55.45
Change-$1.50 (-2.63%)
Volume$56.17K
CapitalizationN/A
HBIO vs IRMD Comparison Chart
Loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
IRMD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
HBIO vs. IRMD commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a Buy and IRMD is a Buy.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (HBIO: $2.17 vs. IRMD: $55.45)
Brand notoriety: HBIO and IRMD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: HBIO: 168% vs. IRMD: 139%
Market capitalization -- HBIO: $184.01M vs. IRMD: $557.04M
HBIO [@Medical Specialties] is valued at $184.01M. IRMD’s [@Medical Specialties] market capitalization is $557.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HBIO’s FA Score shows that 1 FA rating(s) are green whileIRMD’s FA Score has 2 green FA rating(s).

  • HBIO’s FA Score: 1 green, 4 red.
  • IRMD’s FA Score: 2 green, 3 red.
According to our system of comparison, IRMD is a better buy in the long-term than HBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HBIO’s TA Score shows that 2 TA indicator(s) are bullish while IRMD’s TA Score has 5 bullish TA indicator(s).

  • HBIO’s TA Score: 2 bullish, 7 bearish.
  • IRMD’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IRMD is a better buy in the short-term than HBIO.

Price Growth

HBIO (@Medical Specialties) experienced а -23.05% price change this week, while IRMD (@Medical Specialties) price change was -1.33% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.86%. For the same industry, the average monthly price growth was +1.31%, and the average quarterly price growth was -3.19%.

Reported Earning Dates

HBIO is expected to report earnings on Mar 06, 2025.

IRMD is expected to report earnings on Feb 06, 2025.

Industries' Descriptions

@Medical Specialties (-0.86% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IRMD($557M) has a higher market cap than HBIO($184M). IRMD YTD gains are higher at: 17.619 vs. HBIO (-59.439). IRMD has higher annual earnings (EBITDA): 20.8M vs. HBIO (8.03M). IRMD has more cash in the bank: 49.8M vs. HBIO (4.28M). IRMD has less debt than HBIO: IRMD (2.04M) vs HBIO (42.8M). HBIO has higher revenues than IRMD: HBIO (112M) vs IRMD (65.6M).
HBIOIRMDHBIO / IRMD
Capitalization184M557M33%
EBITDA8.03M20.8M39%
Gain YTD-59.43917.619-337%
P/E RatioN/A31.84-
Revenue112M65.6M171%
Total Cash4.28M49.8M9%
Total Debt42.8M2.04M2,095%
FUNDAMENTALS RATINGS
HBIO vs IRMD: Fundamental Ratings
HBIO
IRMD
OUTLOOK RATING
1..100
314
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
10024
SMR RATING
1..100
9241
PRICE GROWTH RATING
1..100
8540
P/E GROWTH RATING
1..100
245
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IRMD's Valuation (18) in the Medical Specialties industry is significantly better than the same rating for HBIO (99) in the Biotechnology industry. This means that IRMD’s stock grew significantly faster than HBIO’s over the last 12 months.

IRMD's Profit vs Risk Rating (24) in the Medical Specialties industry is significantly better than the same rating for HBIO (100) in the Biotechnology industry. This means that IRMD’s stock grew significantly faster than HBIO’s over the last 12 months.

IRMD's SMR Rating (41) in the Medical Specialties industry is somewhat better than the same rating for HBIO (92) in the Biotechnology industry. This means that IRMD’s stock grew somewhat faster than HBIO’s over the last 12 months.

IRMD's Price Growth Rating (40) in the Medical Specialties industry is somewhat better than the same rating for HBIO (85) in the Biotechnology industry. This means that IRMD’s stock grew somewhat faster than HBIO’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for IRMD (45) in the Medical Specialties industry. This means that HBIO’s stock grew somewhat faster than IRMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HBIOIRMD
RSI
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
64%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
61%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
59%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
63%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
IRMD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SCGVX31.950.14
+0.44%
Sands Capital Global Growth Inv
PETZX15.28N/A
N/A
Gabelli Pet Parents'™
HESGX45.96-0.08
-0.17%
Horizon Defensive Core Investor
MSAWX20.07-0.09
-0.45%
Morgan Stanley Inst Asia Opp C
JACNX32.32-0.29
-0.89%
Janus Henderson Contrarian D

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with CTKB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then CTKB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-4.82%
CTKB - HBIO
49%
Loosely correlated
-3.69%
XRAY - HBIO
46%
Loosely correlated
-2.42%
CRL - HBIO
44%
Loosely correlated
-4.35%
KIDS - HBIO
44%
Loosely correlated
+0.87%
PACB - HBIO
42%
Loosely correlated
-10.20%
More

IRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, IRMD has been loosely correlated with LUNG. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if IRMD jumps, then LUNG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRMD
1D Price
Change %
IRMD100%
-2.63%
LUNG - IRMD
41%
Loosely correlated
-4.27%
HBIO - IRMD
38%
Loosely correlated
-4.82%
BLFS - IRMD
36%
Loosely correlated
-9.02%
MASS - IRMD
35%
Loosely correlated
-19.86%
UTMD - IRMD
35%
Loosely correlated
-2.06%
More